Leadership

Matthew Silva, Ph.D.

Chief Executive Officer

Dr. Silva is CEO of Invicro and leads the strategic vision and mission to support the the drug discovery and development community.

Dr. Silva holds a PhD in Biomedical Engineering from Worcester Polytechnic Institute and brings 17 years of diverse imaging experience from pharmaceutical and contract research organizations. Prior to Invicro, he was Senior Director of Translational Biology at Vertex Pharmaceuticals, where he ran the imaging and histopathology groups. Previously, he led imaging groups at Amgen, Millennium and Takeda Pharmaceuticals, focusing on the broad use of imaging biomarkers to support drug discovery and development

CONNECT

Jack Hoppin, Ph.D.

Co-Founder & Distinguished Scientist

Dr. Hoppin is the Co-Founder, Distinguished Scientist and member of the board of directors of Invicro. Dr. Hoppin holds a Ph.D. in Applied Mathematics from the University of Arizona and worked as an Alexander von Humboldt post-doctoral fellow at the Research Center Jülich, Germany. Prior to co-founding Invicro in 2008, Dr. Hoppin served as the VP of Imaging Systems at Bioscan, Inc. He has been working in imaging research for more than 15 years. As an active member of the imaging community, Dr. Hoppin is a member of the World Molecular Imaging Society Board of Trustees.

Dr. Hoppin currently serves as President of Konica Minolta Precision Medicine.

CONNECT

Dr. Christian Lackas

Co-Founder & Distinguished Scientist

Dr. Lackas is the Co-Founder and Managing Partner of Invicro. He is the architect of Invicro’s software platforms and manages the continued development of Invicro’s growing array of software solutions for imaging laboratories. Dr. Lackas holds a Ph.D. (Dr. rer. nat.) in High Energy Physics and a Master (Dipl.-Phys.) in Physics and Computer Science from RWTH Aachen University, Germany. He gathered extensive experience with large scale scientific data acquisition systems during his appointment at DESY, and during his position as Director, Image Application and Software Development at Bioscan, Inc. where he was instrumental for the NanoSPECT/CT project. Dr. Lackas’ offers Invicro advisory and guidance on software solutions (iPACS, iCRO, VivoQuant, etc.) to ensure the highest scientific standards and support researchers in their day-to-day operations.

CONNECT

Jacob Hesterman, Ph.D.

Founding Partner & Head of R&D

Dr. Hesterman is Invicro’s Head of Research and Development. His group focuses on the development of novel image processing, machine learning, & modeling methods and the engineering of robust, efficient image processing tools. These tools are used to extract the quantitative information required to support projects spanning multiple imaging modalities and therapeutic areas. Dr. Hesterman holds a Ph.D. from the University of Arizona’s College of Optical Sciences, having completed a research project in small-animal SPECT at the Center for Gamma Ray Imaging. Prior to joining Invicro, Dr. Hesterman managed Bioscan’s NanoSPECT/CT project for several years while living in Budapest, Hungary, and served as a visiting scientist in the Frangioni Lab at Beth Israel Deaconess Medical Center, a Harvard Medical School Teaching Hospital.

CONNECT

Janna Murgia, M.B.A.

Founding Partner & Chief Operating Officer

Ms. Murgia is a founding member of Invicro and currently serves as its Chief Operating Officer.  Since the company’s founding in 2008, Ms. Murgia has been responsible for organizational infrastructure and development. She oversees a variety of functional areas including finance and accounting, human resources, facilities, general administration and marketing. After beginning her career in nonprofit program and organizational management she transitioned into the corporate sector as cause marketing manager at Macy’s working on national awareness and multi-million dollar fundraising campaigns.  Ms. Murgia’s academic degrees include a BA in Ethics from the College of the Holy Cross and an MBA with honors from the Universiteit Maastricht (Maastricht, The Netherlands). Her master’s work was focused on small business corporate social responsibility.

CONNECT

George Abe

SVP, Emerging Business & Corporate Development

Mr. George Abe is responsible for establishing and growing Invicro’s emerging Advanced Pathology Services business and leading the company’s global corporate development efforts.  Furthermore, he plays a significant role in the integration and coordination of strategic activities with the parent company, Konica Minolta Precision Medicine, Inc.
Mr. Abe has over 25 years of experience in creating value in the life science and high technology industries. He has been involved in numerous transactions including mergers, acquisitions, divestitures, and strategic licensing.  He has also been the CEO of three life science companies, two of which focused on developing novel imaging solutions for oncology and neuroscience research and diagnostics.  Mr. Abe has also served on a variety of private, public, and not-for-profit boards.

Mr. Abe holds a bachelor’s degree in engineering from Trinity College, Hartford, a master’s degree in engineering from the University of Connecticut and is a graduate of the Greater Boston Executive Program at MIT, Sloan School of business.  He currently serves on the Board of Trustees of the Wentworth Institute of Technology.

CONNECT

Ken Bloom, M.D.

CMO, Advanced Pathology & Genomic Services

Dr. Bloom brings more than 30 years of clinical and business experience in pathology, oncology, telemedicine, and bioinformatics. His role will be to help expand, strengthen and commercialize the full-suite of precision medicine capabilities offered within the pathology and genomics markets for Invicro and Ambry Genetics.
Previously, Dr. Bloom was President and Head of Oncology & Immunotherapy for Human Longevity Inc., where his team developed and commercialized an industry leading cancer exome product and commercialized a technique for validating neoantigens predicted from sequencing. Dr. Bloom was also instrumental to the business strategy that evolved Clarient from a start-up to the acquisition by GE Healthcare.

Prior to his industry experience, Dr. Bloom spent 15 years within the academic field holding various appointed positions including Director of Laboratory Operations and Chief Information Officer of the Rush Cancer Institute, Clinical Professor of Pathology at University of Southern California, Keck School of Medicine; and Associate Professor of Pathology at Rush Medical College. Dr. Bloom received his MD from Rush Medical College and his BA from Grinnell College.

CONNECT

Richard Gastineau

JD, LLM, Chief Legal Officer

In his role, Mr. Gastineau is responsible for all legal matters and risk management and is a member of the company’s Global Quality Council.  He counsels Invicro on corporate matters, litigation, human resources and employment law matters, intellectual property and privacy functions.

Mr. Gastineau joined Invicro in 2017 as a part of Invicro’s acquisition of Core Clinical, Inc., a medical imaging core lab that he co-founded.  Mr. Gastineau has been in the clinical research industry since 1995, and has founded, operated and successfully exited several businesses in the technology and healthcare industries and his extensive experience ranges from start-ups to publicly traded companies.  His experience includes time at Quintiles (now IQVIA), ICON, plc, and Y-Prime and he has served on numerous private company and non-profit company boards.

Mr. Gastineau is a graduate of the University of North Carolina and earned his J.D. from the Ohio Northern University School of Law and his LL.M. in Taxation from the Georgetown University School of Law.

CONNECT

Ted Gastineau

EVP Clinical Research

Mr. Gastineau works across Invicro, providing support to Clinical Operations, Scientific and Medical Affairs, and Business Development to help develop study designs and executables for Invicro customers.

With over 30 years of experience in pioneering the use of medical imaging in drug development for Phase I-V projects, Mr. Gastineau has worked worldwide to develop imaging science, advanced accepted study endpoints, and implemented regulatory processes and deliverables.  Mr. Gastineau has delivered more than 50 imaging submissions to U.S. and European regulators.  Prior to Invicro, Mr. Gastineau was the Co-founder of CORE Clinical and was previously President, Global Data Technologies at ICON Plc, including ICON Medical Imaging. Mr. Gastineau also co-founded Beacon Bioscience (acquired by ICON) and Intelligent Imaging (acquired by Quintiles).

CONNECT

Roger Gunn, Ph.D.

EVP, Quantitative Data Sciences

Roger Gunn is an international expert on imaging for disease understanding and drug development. He has a Ph.D. in Applied Mathematics from Warwick University and has worked across Academia (Imperial College London, Oxford University & McGill University), Industry (GSK & Imanova) and Government Labs (MRC Cyclotron Unit).

Roger has made significant contributions to the development of novel imaging biomarkers, quantitative algorithms and software for a wide range of imaging applications with a focus on the neurosciences. He currently holds professorships at Imperial College London and Oxford University and has 200 publications in the field of imaging.

CONNECT

Amanda Harrell

VP, Global Marketing

Ms. Amanda Harrell joined Invicro in January 2018 as Vice President of Global Marketing.  Ms. Harrell brings over 25 years of strategic and analytical marketing experience within the life sciences, healthcare and financial services markets. Ms. Harrell overseas all traditional and digital marketing efforts, public relations, and go-to-market strategies.

Ms. Harrell has served in numerous marketing and business leadership roles at GENEWIZ, Cigna Healthcare, De Lage Landen Financial Services, Fifth Third Bank and Ford Motor Company.

Leading award-winning global marketing teams, Ms. Harrell’s strategic business experience has help corporations realize improved commercial performance, deliver a unique customer centric experience, and launch product innovation via market analytics and competitive intelligence.

CONNECT

Edward J. Hogan Jr.

EVP, Clinical Operations

Mr. Hogan oversees the Clinical Services team including Project Management, Imaging Services, Data Management and Reader Management for early and late phase clinical trials at Invicro.

Mr. Hogan has over twenty-six years of experience in clinical research, managing and executing Phase I through Phase IV imaging trials in both the Pharmaceutical and CRO space. Mr. Hogan brings more than sixteen years of experience in managing clinical operations, including extensive experience leading cross-functional teams, including Operations (Project, Image and Data Management), Engineering (Development and Validation) and Medical and Scientific Services. Mr. Hogan has progressive business experience in building and managing global cross-functional teams supporting clinical trials focusing teams on delivery, accountability, and customer satisfaction while driving quality and process improvements.

CONNECT

Reed Malleck

Chief Financial Officer

Mr. Malleck holds a BS in Finance and an MBA (Operations) from the University of Colorado. Since the year 2000 he has been co-founder, CEO/CFO/COO/Director of a series of early to mid-stage private companies and public companies in the medical devices, healthcare IT, SaaS, RFID and avionics industries.

Mr. Malleck worked at Hewlett-Packard Co as Controller for divisions in the semiconductors, workstations, analytical chemistry instrumentation, multi-user UNIX systems and medical devices (Patient Monitoring Systems) industries. He also managed operations for the Patient Monitoring business. He served in HP’s Asia-Pacific Region as Controller, Tax Manager and Treasury Manager, covering the 33 Field and Factory organizations in the Region, and later also served as Internal Audit Manager for Asia Pacific.

He has served on the Boards of 3 non-profit organizations; Junior Achievement, Loki Clan Wolf Refuge and The Financial Management Association of New Hampshire. He served in the US Army; Military Police Corps – 1971-73.

CONNECT

Kenneth Marek, M.D.

Distinguished Scientist

Dr. Marek is a neurologist with widespread expertise in neurodegenerative disorders. He is internationally recognized as an expert in imaging of neurodegenerative disorders and has made significant contributions to early detection and diagnostic use of radiotracers for these disorders for PD, AD, HD and other disorders. He has developed novel clinical design for brain imaging studies and has been the Principal Investigator in several multicenter trials including PPMI and PARS.

Kelly Orcutt, Ph.D.

VP, Research Services

Dr. Orcutt is Invicro’s VP of Discovery Research. She holds a Ph.D. in Chemical Engineering from MIT and has expertise in pharmacokinetic modeling, radiochemistry, and preclinical imaging across multiple imaging modalities (PET/SPECT/CT). Dr. Orcutt supports the design, execution, analysis, and interpretation of single- and multi-site preclinical imaging studies and first-in-human studies of novel radiolabeled biologics. She also manages the integration of modeling & simulation of in vivo pharmacokinetics with preclinical imaging to better understand mechanisms of drug PK, distribution, targeting and efficacy to guide translational efforts. Dr. Orcutt holds a B.S. from Johns Hopkins University. She completed her graduate work at MIT in Dane Wittrup’s lab, where she used a combination of protein engineering and mathematical modeling approaches to engineer a novel radioimmunotherapy approach to treating cancer. Following her graduate work, she worked as a postdoctoral fellow at Harvard Medical School in the Center for Molecular Imaging to develop cancer therapeutic and imaging agents.

CONNECT

Jan Passchier, Ph.D.

EVP, Global Head of Chemistry

Jan is an expert in radiochemistry applied to imaging and drug development. He completed a PhD in PET radiochemistry from Groningen University prior to moving to GlaxoSmithKline where he worked closely with project teams to identify and develop novel tool compounds for a large variety of CNS, metabolic and respiratory indications.

Jan played a significant role in the design and realization of the GlaxoSmithKline Clinical Imaging Centre where he headed the chemistry group. Following the spin-out of the centre to Imanova Ltd, now part of Invicro, he took on the overall operational responsibility for the business.

Jan has a keen interest and deep understanding of the application of molecular imaging to disease understanding and drug development.

CONNECT

Eugenii (Ilan) Rabiner, M.D.

EVP, Head of Translational Applications

Ilan is a psychiatrist and psychopharmacologist who was part of the team that set up the GlaxoSmithKline Clinical Imaging Centre, which transitioned to become Imanova in Sep 2011. Ilan spent 10 years at GlaxoSmithKline, and was head of Clinical Imaging Applications at the Translational Medicine and Technologies group.

Ilan received a BSc in Physiology and Medical Biochemistry and a MBBCh, from the University of the Witwatersrand, and specialist training in psychiatry at the University of Cape Town. He was trained in molecular imaging at the MRC Cyclotron Unit, Hammersmith Hospital, London.

Ilan’s research interests focus on the application of molecular imaging to human pathophysiology, psychopharmacology and central nervous system drug development. He is an author of >140 peer reviewed publications.

CONNECT

John Seibyl, M.D.

Distinguished Scientist

Dr. Seibyl is an international expert on PET and SPECT imaging for neurodegenerative disorders. He is past President of the Brain Imaging Council of the Society of Nuclear Medicine. Dr. Seibyl is dually-boarded in Nuclear Medicine and Psychiatry and has twenty years of experience in clinical studies. He has made significant contributions to development of visual and quantitative analysis for PET imaging in neurodegenerative and neuropsychiatric disorders. Along with Dr. Marek he has directed and continues to direct several international multicenter imaging studies. Dr. Seibyl is an author on over hundred publications on CNS imaging.

CONNECT

Roughan Sheedy

Chief Commercial Officer

Roughan has nearly 20 years of experience in the life sciences sector, and joined Imanova (now Invicro London) as CFO in 2013. Roughan’s career has encompassed senior Finance and Commercial roles, working in a range of environments – from private equity backed business to listed companies. Prior to Invicro, Roughan’s career encompassed time with LGC and IVAX in the UK.

Roughan completed his Batchelor’s degree in Trinity College, Dublin, and also holds an MA in Accounting and Finance from Lancaster University. In addition to being a Chartered Management Accountant, Roughan is also an Associate of the Chartered Institute of Marketing.

CONNECT